2019 OBJECTIVES STRATEGIC FOCUS OVER THE NEXT 12 MONTHS: Focused on high-margin, value-added branded medical and adult-use derivative products.
2019 OBJECTIVES
-
Complete product R&D, formulation and manufacturing activities at Dosecann in preparation for the legalization of derivative products
-
Complete construction on all ongoing cultivation assets, including our joint venture partner Sunens’ state-of-the-art greenhouse facility, expected to
provide supply of over 100,000 kg of cannabis in 2020
-
Continue to support the rollout of Kolab and Robinsons and build brand awareness
-
Opportunistically expand our footprint in international markets to facilitate the sale of CBD derived from Inverell, our large-scale hemp cultivation operation in Uruguay
There is no doubt: Auxly is moving from the design phase to construction followed by the production phase. By the summer of 2019, we should have more progressive news on the construction status, this will boost the share price to a different level. As the news of the production level started to surface we will hit another share price range, adequate to the overall conglomerate business of Auxly. Let's be positive and wish the management and all employees success.
All cannabis companies have gone through similar exercise until production time. Aurora is still in the construction phase by Edmonton international airport 2 years after announcing the project in 2017.
Auxly strategic focus is on medical and adult-use derivatives, that where your margin is quite high.